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Abstract
Suppose we have a binary treatment used to influence an outcome. Given data from
an observational or controlled study, we wish to determine whether or not there exists
some subset of observed covariates in which the treatment is more effective than the
standard practice of no treatment. Furthermore, we wish to quantify the improvement
in population mean outcome that will be seen if this subgroup receives treatment and
the rest of the population remains untreated. We show that this problem is surprisingly
challenging given how often it is an (at least implicit) study objective. Blindly applying
standard techniques fails to yield any apparent asymptotic results, while using existing
techniques to confront the non-regularity does not necessarily help at distributions where
there is no treatment effect. Here we describe an approach to estimate the impact of
treating the subgroup which benefits from treatment that is valid in a nonparametric
model and is able to deal with the case where there is no treatment effect. The approach is
a slight modification of an approach that recently appeared in the individualized medicine
literature.
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1 Introduction
Traditionally, statisticians have evaluated the efficacy of a new treatment using an average
treatment effect which compares the population mean outcomes when everyone versus no
one is treated. While analyses of marginal effect often successfully identify whether or not
introducing a treatment into the population is beneficial, these analyses underestimate the
overall benefit of introducing treatment into the population when treatment is on average
harmful in some strata of covariates. A treatment need not have adverse physiological side
effects for the treatment effect to be negative: it will be negative if the administration of an
inferior treatment under study precludes the administration of a superior treatment. To avoid
this problem, researchers often perform subgroup analyses to see if the treatment effect varies
between different strata of covariates [1, 2]. Many investigators consider subgroups defined
by a single covariate at a time [3, 4], though there is a growing trend toward defining these
subgroups using multiple baseline covariates [5, 6].
Subgroup analyses have led to much disagreement between clinicians and statisticians.
As has been highlighted elsewhere [2], A R Feinstein eloquently described this controversy
as follows:
“The essence of tragedy has been described as the destructive collision of two
sets of protagonists, both of whom are correct. The statisticians are right in
denouncing subgroups that are formed post hoc from exercises in pure data
dredging. The clinicians are also right, however, in insisting that a subgroup
is respectable and worthwhile when established a priori from pathophysiological
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principles.” [7]
While learning about subgroup specific effects is clearly important when they exist, the con-
cerns of statisticians are understandable. When the analysis is not prespecified, statistical
significance procedures tend not to be reliable [2, 3, 8]. To exemplify the concerns on this
issue, P Sleight shows that the strong marginal effect of aspirin for preventing myocardial
infarction changes to a negative effect in two subgroups when these subgroups are defined
by astrological sign [9]. While it is clearly unlikely in practice that astrological sign yields
heterogeneous subgroups, one would hope that a statistical procedure would be sufficiently
robust to inform the user that astrological sign is not in fact associated with efficacy. Some
have argued that sample splitting methods would help robustify a procedure to “data dredg-
ing” by either humans or overfitting by an algorithm [10, 11, 12].
In a related literature, optimal individualized treatment strategy have been developed to
formalize the process of allowing treatment decisions to depend on baseline covariates in
a rigorous manner [13]. An individualized treatment strategy is a treatment strategy that
makes a treatment decision based on a patient’s covariates. Often the objective for such
treatments is to optimize the population mean outcome under the given treatment strategy [14,
15]. For binary treatment decisions in a single time point setting, an optimal individualized
treatment strategy is any individualized treatment strategy which treats all individuals for
which the average treatment effect is positive in their strata of covariates and does not treat
anyone for whom the average treatment is negative in their strata of covariates. Estimating the
population mean outcome under the optimal individualized treatment rule has been shown to
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be non-regular when the optimal treatment strategy is not unique [16, 17]. This non-regularity
causes standard semiparametric estimation approaches to fail. Despite the complexity of this
estimation problem, [18] shows that one can develop a slower than root-n rate confidence
interval for the mean outcome under the estimated optimal individualized treatment rule using
a bootstrap procedure, and [17] shows how to obtain a root-n rate confidence interval for the
actual optimal individualized treatment strategy. Often one can use the same confidence
interval for these two estimation problems because one can estimate the optimal treatment
strategy consistently (in terms of the strategy’s mean outcome) at a faster than root-n rate
[17].
As the reader may have noticed, two literatures are analogous – if one defines the optimal
subgroup as the subgroup of covariate strata in which the treatment effect is positive, then
the optimal subgroup is (up to covariate strata for which there is no treatment effect) equal
to the group of individuals for which an optimal treatment rule suggests treatment. However,
the subgroup literature has not confronted the problem of developing high powered inference
when an arbitrary algorithm is used to develop the subgroup – while the sample splitting
procedure described in [12] is valid for a single sample split provided the optimal subgroup
is not empty, subsequently averaging across sample splits will not yield valid inference (see
the discussion of the use of cross-validation for individualized treatment rules in [19]). Thus
there is a significant loss of statistical power in such a procedure.
In this work, we aim to satisfy the desires of both statisticians and clinicians – we seek
a statistically valid subgroup analysis procedure which allows the incorporation of both the
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subject matter knowledge of physicians and the agnostic flexibility of modern statistical learn-
ing techniques. Our subgroup analysis procedure will return an estimate of the population
level effect of treating everyone in a stratum of covariates with positive treatment effect ver-
sus treating no one. This succinctly characterizes the effect of optimally introducing a given
treatment into a population. To estimate this quantity, we modify an estimator from the in-
dividualized treatment literature which overcomes a statistical challenge that typically arises
when trying to estimate quantities involving individualized treatment rules [17]. We will
show that an additional statistical challenge arises when trying to use a variant of this estima-
tor in the subgroup setting. We will then show how to overcome this challenge.
2 Statistical formulation
Suppose we observe baseline covariates W , an indicator of binary treatment A, and an out-
come Y occuring after treatment and covariates. Let P0 be some distribution for O ≡
(W,A, Y ) in a nonparametric statistical model M that at most places restrictions on the
probability of treatment given covariates. We observe n independent individuals O1, . . . , On
drawn from P0. Define b0(W ) = EP0 [Y |A = 1,W ] − EP0 [Y |A = 0,W ]. Under causal as-
sumptions not elaborated here, b0(W ) can be identified with the additive effect of treatment
on outcome if everyone versus no one in a strata of covariates W receives treatment [20]. We
use sg to denote any (measurable) subset of the support of W . Define
Ψsg(P0) ≡
∫
sg
b0(w)dP0(w).
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Under causal assumptions, Ψsg(P0) is identified with the difference (i)-(ii) between (i) the av-
erage outcome if the only individuals receiving treatment in the population are those whose
covariates fall in sg and (ii) the average outcome if no one in the population receives treat-
ment. Drawing parallels to optimal individualized treatment strategies, Ψsg(P0) is maximized
at sg if and only if sg includes precisely those individuals with covariate w such that b(w) > 0
and does not include those with b(w) < 0 [14, 15]. The maximizer is non-unique at so-called
“exceptional laws”, i.e. distributions for which b(W ) = 0 with positive P0 probability [15].
Define Ψ(P0) ≡ maxsg Ψsg(P0). Throughout we define bP , Ψsg(P ), and Ψ(P ) at arbitrary
P ∈M analogously to b0, Ψsg(P0), and Ψ(P0).
3 Breakdown of “standard” estimators
We now describe how the standard semiparametric estimation roadmap seems to suggest we
estimate Ψ(P0). A function known as the efficient influence function (EIF) often plays a key
role in this estimation procedure. While we avoid a formal presentation of the derivation of
EIFs here, the key result about EIFs is that they typically yield the expansion
n1/2[Ψ(Pˆn)−Ψ(P0)] = −n1/2
∫
IFPˆn(o)dP0(o) + n
1/2 Rem(Pˆn, P0), (1)
where Pˆn is an estimate of P0, IFPˆn is the EIF of Ψ at Pˆn, and Rem(Pˆn, P0) is a remainder
that plausibly converges to zero faster than n−1/2. We will present an explicit expression for
IFPˆn at the end of this section, but for now we state that the corresponding remainder term is
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given by
Rem(Pˆn, P0) =
1∑
a˜=0
(2a˜− 1)
∫
I(w ∈ sgn)
[
1− P0(a˜|w)
Pˆn(a˜|w)
] (
EPˆn [Y |a˜, w]− EP0 [Y |a˜, w]
)
dP0(o)
+ Ψsgn(P0)−Ψsg0(P0),
where sgn is the optimal subgroup under Pˆn. The first term on the right is a double robust term
[21] that shrinks to zero faster than n−1/2 if the outcome regression and treatment mechanism
are estimated well. The second term requires that the optimal subgroup can be estimated
well and is plausible if the stratum specific treatment effect function does not concentrate
too much mass near zero (mass at zero is not problematic since any subgroup decision for
these strata is optimal). See Theorem 8 of [17] for precise conditions under which this term
is small. In principle sgn need not be an optimal subgroup under Pˆn, i.e. one can replace
Ψ(Pˆn) on the left-hand side of (1) with Ψsgn(Pˆn) without changing the expansion. We ignore
such considerations here for brevity, though discussion in a closely related problem is given
in [19].
A one-step estimator of the form ψn ≡ Ψ(Pˆn)+ 1n
∑n
i=1 IFPˆn(Oi) aims to correct the bias
on the right-hand side of (1) by adding an estimate of that expectation, yielding
√
n [ψn −Ψ(P0)] ≈ 1√
n
n∑
i=1
(
IFPˆn(Oi)−
∫
IFPˆn(o)dP0(o)
)
, (2)
where the above approximation is valid provided n1/2 Rem(Pˆn, P0) converges to zero in prob-
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ability. For a general parameter Ψ, targeted minimum loss-based estimators (TMLEs) can
be seen to follow the above prescribed formula, with the estimate Pˆn carefully chosen so
that the empirical mean of IFPˆn is zero, and thus the final estimator is the plug-in estimator
ψn = Ψ(Pˆn) [22]. A detailed exposition of efficiency theory is given in [23].
We cannot apply the central limit theorem to the right-hand side of (2) without further
conditions because the right-hand side is a root-n empirical mean over functions which de-
pend on the data. We now give sufficient conditions. Suppose that IFPˆn has a limit IF∞ in the
sense that
(
IFPˆn − IF∞
)2 has P0 expectation converging to zero. (Lim)
Typically IF∞ = IFP0 . If Pˆn is not allowed to heavily overfit the data, the instances of IFPˆn
on the right-hand side of (2) can be replaced with IF∞. The conditions on Pˆn which prevent
overfitting are given by the empirical process conditions presented in Part 2 of [24]. If
VarP0 [IF∞(O)] > 0, (V+)
then the central limit theorem can be used to see that n1/2[ψn−Ψ(P0)] converges to a normal
distribution with mean zero and variance VarP0 [IF∞(O)]. Under these conditions, Ψ(P0)
falls in ψn±1.96 σn√n with probability approaching 0.95, where σ2n is the empirical variance of
IFPˆn applied to the data. If VarP0 [IF∞(O)] is zero, then n
1/2[ψn − Ψ(P0)] converges to zero
in probability, but there is no guarantee that ψn ± 1.96 σn√n contains Ψ(P0) with probability
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approaching 0.95: both
√
n[ψn−Ψ(P0)] and σn are converging to zero, but coverage depends
on the relative rate of convergence of the two quantities.
We now argue that it is unlikely that both (Lim) and (V+) hold. When Pˆn is non-
exceptional,
IFPˆn(o) = I[bPˆn(w) > 0]
[
2a− 1
Pˆn(a|w)
(Y − EPˆn [Y |A = a,W = w]) + bPˆn(w)
]
−Ψ(Pˆn).
If Pˆn is exceptional, the above definition of IFPˆn can still be used and the same central limit
theorem result about (2) holds under (Lim) and (V+), though in truth Ψ is not smooth enough
at Pˆn for an efficient influence function to be well-defined [16, 17]. In light of the above
expression, the validity of (Lim) will typically require I[bPˆn(W ) > 0] to have a mean-square
limit. Suppose the data is drawn from an exceptional law where the treatment effect is zero
on some set S0. In that case we do not expect I[bPˆn(W ) > 0] to converge to anything on S0
since likely bPˆn(w) does not converge to 0 strictly from above or below at any given w for
which b0(w) = 0.
Now consider the case where treatment is always harmful, i.e. b0(W ) < 0 with proba-
bility 1. In this case b0(W ) ≥ 0 with probability 0, and so we would expect the indicator
that bPˆn(w) is positive converges to zero if Pˆn is a good estimate of P0. But in this case the
subgroup that should be treated is empty so that if the limit IF∞ exists then it is zero almost
surely and (V+) does not hold.
Finally, consider the intermediate case where there is no additive treatment effect within
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any strata of covariates, i.e. b0(w) = 0 for allw. If on any positive probability set convergence
occurs from both above and below, then we do not expect (Lim) to hold. If bPˆn(w) converges
to zero from below for all w, then we expect (Lim) to hold with IF∞ equal to the constant
function zero and (V+) not to hold. If, for each w, bPˆn(w) converges to zero from either
strictly above or strictly below and the set of covariates for which the convergence occurs
from above happens with positive probability, then we expect (Lim) and (V+) to hold.
4 Avoiding the need for (Lim) and (V+)
In this section, we present an estimator which overcomes both (Lim) and (V+). We first
present an estimator which does not require (Lim), and then argue that a simple extension of
this estimator also does not require (V+).
This estimation strategy is similar to the one-step estimator presented in the previous
section, but designed to estimate the parameter in an online fashion which eliminates the
need for convergence. The online one-step estimator was originally presented in [25], and
was refined in [17] to deal with cases where the convergence of the sort required by (Lim)
fails to hold. The method will be presented in full generality in a forthcoming paper.
Let Pˆ in represent an estimate of P0 based on observations O1, . . . , Oi. The stabilized
online one-step estimator for Ψ(P0) is given by
ψstn ≡
σ¯n
n− `n
n−1∑
i=`n
Ψ(Pˆ in) + IFPˆ in(Oi+1)
σˆi
. (3)
where `n is some user-defined quantity that may or may not grow to infinity but must sat-
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isfy n − `n → ∞, σˆ2i represents an estimate of the variance of IFdiPˆ in(O) based on obser-
vations O1, . . . , Oi, and σ¯n is the harmonic mean 1/[ 1n−`n
∑n−1
i=`n
σˆ−1i ] of σˆ`n , . . . , σˆn−1. We
now wish to apply the martingale central limit theorem [26] to understand the behavior of
√
n− `nσ¯−1n [ψstn − Ψ(P0)]. As each term in the sum defining ψn has variance converging to
1 due to the stabilization by σˆi, the validity of our central limit theorem argument does not
rely on an analogue of (Lim). It does, however, rely on an analogue of (V+). The primary
condition we would use to establish the validity of the central limit theorem argument is that
the set of σˆ2i are consistent for VarP0
[
IFPˆ in(Oi+1)
]
as i gets large and that there exists some
δ > 0 such that
VarP0
[
IFPˆ in(Oi+1)
]
> δ2 > 0 for all i with probability approaching 1. (V+’)
The former condition holds under a Glivenko-Cantelli condition which is discussed in Theo-
rem 7 of [17]. Under these conditions, Section 7 of [17] (especially Lemma 6) shows that
√
n− `n [ψstn −Ψ(P0)]
σ¯n
≈ 1√
n− `n
n−1∑
i=`n
IFPˆ in(Oi+1)−
∫
IFPˆ in(o)dP0(o)
σˆi
provided the same conditions needed for (2) hold. The above approximation is accurate up
to a term that goes to zero in probability. The martingale central limit theorem can now be
applied to establish the validity of the 95% confidence interval CIst ≡
[
ψstn ± 1.96 σ¯n√n−`n
]
.
We refer the reader to Theorem 2 in [17] for a sense of the formal conditions needed to prove
this result. If the treatment effect is negative for all strata of covariates, then (V+’) will not
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hold if Pˆ in is a reasonable estimate of P0 in the sense that the estimated optimal subgroup
converges to the empty set. Similarly, we have no guarantee that (V+’) will hold if b0(W ) is
zero almost surely.
Suppose that we are not willing to assume that (V+’) holds. A natural approach is to
redefine the inverse weights to equal σˆi(δ) ≡ σˆi ∨ δ for some fixed δ > 0. We then define
σ¯n(δ) to be equal to the harmonic mean of σˆ`n(δ), . . . , σˆn−1(δ) and ψstn(δ) as in (3) but with
σˆi and σ¯n replaced by σˆi(δ) and σ¯n(δ). Clearly σ¯n(δ) ≥ σ¯n, and thus the confidence interval
CIst(δ) ≡
[
ψstn(δ)± 1.96 σ¯n(δ)√n−`n
]
is no wider than that CIst, though it may have a different
midpoint. We conjecture that this confidence interval is conservative when the truncation
scheme is active so that σ¯n(δ) > σ¯n, though proving this result has proven challenging.
To give the reader a sense of why we have hope that this conjecture will hold, we show
in the appendix that adding normal noise (with random variance depending on the sample)
to ψn(δ) can yield a valid 95% confidence interval for Ψ(P0). It then seems reasonable
that removing the noise can only improve coverage. Readers whose primary concern is the
theoretical soundness of an inferential procedure can apply the estimator in the appendix
and rest assured that their confidence interval will be valid provided the optimal subgroup is
estimated sufficiently well and a double robust term is small. Nonetheless, the type I error
gains by not using this noised estimator, which we will see provided the conjecture holds,
would seem to imply that our original unnoised confidence interval performs better than the
noised interval.
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5 Simulation study
5.1 Methods
We now present a simulation study conducted in R [27]. Our simulation uses a four-dimensional
covariate W drawn from a mean zero normal distribution with identity covariance matrix.
Treatment A is drawn according to a Bernoulli random with probability of success 1/2, in-
dependent of baseline covariates. The outcome Y is Bernoulli, and the outcome regressions
considered in our primary analysis are displayed in Table 1.
Simulation logitE[Y |A,W ] Ψ(P0) P0 (b0(W ) = 0) P0 (b0(W ) < 0)
N1 W1 +W2 0 1 0
N2 −0.2A[(W1 − z0.8)+]2 0 0.80 0.20
N3 −0.25A 0 0 1
A1 0.8A 0.19 0 0
A2 AW+1 − AW+2 0.06 0.25 0.38
A3 AW1 0.09 0 0.50
Table 1: Data generating distributions for simulation. Decimals rounded to the nearest hun-
dredth. For N2, z0.8 ≈ 0.84 is the 80th percentile of a standard normal distribution. We use
x+ to denote the positive part of a real number x.
We compare two estimators of Ψ(P0). The first is the stabilized one-step estimator. We
truncate the inverse weights at 0.1, 0.001, and 10−20. The results were essentially identical
for truncations of 10−3 and 10−20, and thus we only display the results for the truncation of
10−3. We set `n = n/10, and to speed up the computation time we estimated the subgroup
and outcome regression using observations O1, . . . , Ok(i)n/10 for all i ≥ `n, where k(i) is the
largest integer such that k(i)n/10 < i (see Section 6.1 of [17] for more details). The second
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estimator is a ten-fold cross-validated TMLE (CV-TMLE). This estimator is analogous the
CV-TMLE for the mean outcome under an optimal treatment rule as presented in [19], but is
modified to account for the fact that Ψ(P0) is equal to this quantity minus the mean outcome
when no one in the population is treated. We truncate the variance estimates for this esti-
mator at the same values as considered for the stabilized one-step estimator. Following the
theoretical results in [28], we can formally show that this estimator is asymptotically valid
when cross-validated analogues of (Lim) and (V+) hold.
We estimate the blip function using the super-learner methodology as described in [29].
Super-learner is an ensemble algorithms with an oracle guarantee ensuring that the resulting
blip function estimate will perform at least as well as the best candidate in the library up to a
small error term. We use a squared error loss to estimate the blip function, and use as candi-
date algorithms SL.gam, SL.glm, SL.glm.interaction, SL.mean, and SL.rpart
in the R package SuperLearner [30]. The outcome regression E[Y |A,W ] is estimated
using this same super-learner library but with the log-likelihood loss to respect the bounds
on the outcome. The probability of treatment given covariates was treated as known and the
known value was used by all of the estimators.
We also compare our estimators to the oracle estimator which a priori knows the optimal
subgroup. In particular, we use a CV-TMLE for Ψsg0(P0) in which we treat sg0 as known.
The estimation problem is regular in this case so that we expect the corresponding confidence
intervals to have proper coverage at exceptional laws. We truncate the variance estimate at
the same values as for the other methods.
14
5.2 Results
Figure 1 displays the coverage of the confidence interval lower bounds of the various esti-
mation strategies. All methods appear to achieve proper 97.5% lower bound coverage, with
the stabilized one-step and the non-oracle CV-TMLE estimators generally being conserva-
tive. This conservative behavior is to be expected given that both of these sample splitting
procedures need to estimate the optimal subgroup, and thus in any finite sample are expected
to be negatively biased due to the resulting suboptimal subgroup used from the estimate.
The oracle CV-TMLE attains the nominal coverage rate for alternative distributions, and for
non-alternatives is also conservative.
We now verify the tightness of the lower bounds for the alternative distributions A1, A2,
and A3. Figure 2 shows the power for the test of H0 : Ψ(P0) = 0 against H1 : Ψ(P0) >
0, where the test was conducted using the duality between hypothesis tests and confidence
intervals. We see that the stabilized one-step is slightly less powerful than the non-oracle
CV-TMLE. This is likely due to the online nature of the stabilized one-step estimator relative
to the CV-TMLE. Nonetheless, the power loss is not large and the fact that we have actual
theoretical results for this estimator even at exceptional laws should make up for this slight
loss of power.
Figure 3 displays the two-sided coverage of the 95% confidence intervals. One could
argue that upper bound coverage is not interesting for the null distributions, given that any
failure of the upper bound of the confidence interval to cover Ψ(P0) = 0 requires this upper
bound to be negative. Hence we can always obtain proper upper bound coverage at null dis-
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Figure 1: Coverage of 97.5% lower confidence intervals for the impact of treating the optimal
subgroup versus sample size. Horizontal axis on a log scale. All methods (approximately)
achieve nominal coverage, with the stabilized one-step and non-oracle CV-TMLE generally
being conservative.
tributions by ensuring that the upper bound of our confidence interval respects the parameter
space of Ψ, i.e. is nonnegative. Nonetheless, the coverage of the uncorrected two-sided con-
fidence intervals (upper bound may be negative) is useful for detecting a lack of asymptotic
normality of the estimator sequence. While the stabilized one-step has two-sided coverage
above 0.95 for all distributions at all sample sizes of at least 500, the coverage for the unad-
justed non-oracle CV-TMLE confidence interval falls at or below 0.90 for N1 and N2 at all
sample sizes. This is in line with our lack of asymptotic results for the non-oracle CV-TMLE
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Figure 2: Power for rejecting a test of H0 : Ψ(P0) = 0 versus H1 : Ψ(P0) > 0 at the
0.025 level at different sample sizes. Horizontal axis on a log scale. All methods have power
increasing to 1. The stabilized one-step has lower power than the non-oracle CV-TMLE,
though its power is typically more comparable to the stabilized one-step relative than the
oracle CV-TMLE which knew the optimal subgroup from the outset.
at exceptional laws.
We now consider the two-sided coverage for the alternative distributions A1, A2, and A3.
The stabilized one-step confidence intervals have coverage that improves with sample size,
though the improvement appears slow. The coverage is near nominal at a sample size of 4000
for all three simulations. In light of Figure 1, essentially all of the coverage deficiency is a
result of a failure of the upper bound. This makes sense given that our estimator relies on
a second-order term measuring a linear combination of the difference in impact of treating
the estimated subgroups (estimated on increasing chunks of data) versus treating the optimal
subgroup. While this term often reasonably shrinks to zero faster than n−1/2, in finite samples
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Figure 3: Coverage of 95% two-sided confidence intervals for the impact of treating the
optimal subgroup versus the average confidence interval width (standardized so that the max-
imum width in a given sample size-data generating distribution pair is 1). The stabilized one-
step confidence intervals have nominal coverage for all null distributions, and have coverage
approaching nominal for all alternative distributions. The non-oracle CV-TMLE achieves
near nominal coverage for all alternative distributions, though has below nominal coverage
of approximately 90% for all of the null distributions.
this term can hurt the upper bound coverage. The non-oracle CV-TMLE confidence intervals,
on the other hand, attain near nominal coverage at large sample sizes. This is to be expected
at the non-exceptional laws A1 and A3 given that we can prove asymptotic normality in
this case. We do not have an asymptotic result supporting the method’s proper coverage for
exceptional law A2, though this is an interesting area for future work.
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6 Discussion
We have studied the statistical challenges associated with estimating the additive effect of
treating the subgroup of individuals with positive stratum specific additive treatment effect.
We showed that these challenges are similar to those arising when estimating the mean out-
come under an optimal individualized treatment strategy. Indeed, the individuals treated by
the strategy which maximizes the population mean outcome are the same individuals who
belong to the optimal subgroup. An additional challenge arises when one wishes to consider
the relative measure giving the additive effect of treating only those individuals in the optimal
subgroup versus treating no one in the population. In this case the parameter of interest is es-
timable at a faster than root-n rate for some data generating distributions. Procedures which
yield root-n rate confidence intervals tend to fail in this setting due to the need to estimate
both the (in truth empty) optimal subgroup and the variance of the estimate of the impact of
treating this subgroup: generally the subgroup estimate will converge to the empty set and
the variance estimate will converge to zero, but there is no guarantee that the relative rate of
convergence of the two will yield valid inference.
Despite this added inferential challenge, we argue that obtaining a confidence interval
for the impact of treating the optimal subgroup requires only minor modification to the con-
fidence interval for the mean outcome when only the optimal subgroup is treated. In par-
ticular, we propose truncating the estimated variance in the martingale sum used in [17] at
some constant δ > 0. If the truncation is not active, which will typically be true for al-
ternative distributions under which there exists a subgroup for which the treatment effect is
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positive and is arguably true for many null distributions as well, then, under standard regu-
larity conditions, we obtain root-n rate inference with coverage approaching 0.95. If the data
is generating according to an alternative distribution for which there is a non-null (positive or
negative) treatment effect within all strata of covariates, then our estimator is asymptotically
efficient and, provided the truncation is not active, our confidence interval is asymptotically
equivalent to a standard Wald-type confidence interval (see Corollary 3 in [17]). We expect
our confidence interval to be conservative when the truncation is active, though we leave this
as a conjecture. We have instead shown that adding noise to our estimator yields a confi-
dence interval with proper 95% coverage, though we suggest using the unnoised estimator in
practice.
One could imagine several alternative solutions to the described inferential challenge.
One such solution is to ensure that the variance of our estimator minus the truth, scaled by
root-n, is positive as sample size grows. This can be accomplished by changing the definition
of the optimal subgroup to ensure that this subgroup is not too small, e.g. contains at least
10% of the population. One can show via a change of variables that estimating the mean
outcome under such a constrained subgroup is equivalent to estimating the mean outcome
under an optimal rule which can treat at most 90% of the population, see [31]. Estimating
this alternative constrained parameter is still difficult when the optimal subgroup is non-
unique, though there is little risk of degenerate first-order behavior in this case. To construct
confidence intervals despite the non-uniqueness of the optimal subgroup, one can combine
the results in [31] with the stabilized one-step estimator presented in [17].
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A cross-validated TMLE, closely related to that presented in [28], outperformed the
method proposed in this paper in many simulation settings. Nonetheless, we do not have
any asymptotic results about the CV-TMLE at exceptional laws, in contrast to the estimator
presented in this paper for which we do have such results. This estimator’s lack of asymp-
totic normality at such laws was evident in our simulation. We view a careful study of this
estimator’s behavior at exceptional laws to be an important area for future research. In a
forthcoming work, we will present a stabilized TMLE that has the same desirable asymp-
totic properties of the stabilized one-step estimator but, like the CV-TMLE, is a substitution
estimator (thereby forcing the estimate to respect the parameter space).
One could imagine considering other parameters relating to the optimal subgroup that
we have presented in this paper. For example, investigators may be interested in estimating
the impact of treating everyone in the optimal subgroup on some secondary outcome Y˜ .
Each such parameter yields a new estimation problem and, in our experience, many of these
problems still face at least one of the two primary challenges that we faced in this paper. In
particular, these problems are often non-regular when the optimal subgroup is non-unique,
and may have degenerate first-order behavior when the optimal subgroup is empty.
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Appendix
Let {Zi : i = 1, . . . ,∞} be a sequence of i.i.d. normal random variable independent of all
other sources of randomness under consideration. Let
ψ˜stn(δ) =
σ¯n
n− `n
n−1∑
i=`n
Ψ(Pˆ in) + IFPˆ in(Oi+1) +
√
(δ2 − σˆ2i )+Zi
σˆi(δ)
,
where x+ is the positive part of a real number x. Observe that each term in the sum on the
right-hand side above has variance approximately 1 (approximately because σˆi is only an
estimate of VarP0 [IFPˆ in(O)]). It will then follow that, under regularity conditions, we can ap-
ply the martingale central limit theorem appearing in [26] to show that
[
ψ˜stn(δ)± 1.96 σ¯n(δ)√n−`n
]
has coverage approaching 95% for Ψ(P0). These regularity conditions are the same as those
used to establish the validity of CIst, except that they do not require (V+’) to hold. Note the
similarity to CIst(δ), though the above confidence interval is centered about ψ˜n(δ) rather than
ψn(δ).
We now relate the noised ψ˜stn to the unnoised ψ
st
n . Conditional on the data, ψ˜
st
n(δ) is equal
in distribution to ψstn(δ) +
σ˜n(δ)√
n−`nZ1, where σ˜
2
n(δ) ≡ 1n−`n
∑n−1
i=`n
(δ2−σ2i )+
σˆ2i ∨δ2
. That is, ψ˜stn(δ) is
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equal to ψn(δ) plus normal noise, where the variance of the normal noise depends on the data.
If the truncation is not active, then the variance of this noise is zero. Otherwise, the variance
is positive, but the sign of the noise is independent of the data. Thus it seems reasonable to
expect that the unnoised ψstn provides a better estimate of Ψ(P0) than ψ˜
st
n . It is for this reason
that we expect the unnoised confidence interval CIst(δ) to have coverage at least 0.95 in large
samples.
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